TG THERAPEUTICS, INC.

TGTX - CIK 0001001316

Market cap$7.14 B

Rank#1140

SEC filings1,133

TG THERAPEUTICS, INC. trades as TGTX and has a market capitalization of $7.14 B, making it the #1140 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $616.29M, up 87.3% from the prior year and net income of $447.20M. This page tracks TG THERAPEUTICS, INC. through 1,133 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$616.29MFY 2025

Net income (latest FY)$447.20MFY 2025

Operating cash flow (latest FY)-$24.77MFY 2025

Total assets (latest FY)$1.06BFY 2025

Net margin72.6%latest FY

Financial performance

Over the last 9 fiscal years TG THERAPEUTICS, INC.'s revenue grew from $152.00K to $616.29M, a compound annual growth rate of 151.7%. Net profit margin expanded from -5204.1% to 72.6% over the same period - every figure below comes from the company's audited annual filings.

TGTX annual revenueView details

Key statistics

Market cap: $7.14 B
Share price (derived)market cap / shares outstanding: $46.62
P/E ratio (trailing FY): 16.0
EPS (diluted)FY 2025: $2.77
Shares outstandingas of 2026-05-01: 0.15B
Total equityas of 2026-03-31: $583.13M
Return on equity: 76.7%
Long-term debtas of 2026-03-31: $745.14M

Latest filings

Filing	Type	Filed
Quarterly report	10-Q	2026-05-06
Major company event	8-K	2026-05-06
Proxy statement	DEF 14A	2026-04-30
SCHEDULE 13G	-	2026-04-29
SCHEDULE 13G/A	-	2026-03-27
Major company event	8-K	2026-03-20
Annual report	10-K	2026-02-27
Major company event	8-K	2026-02-26

Browse the full filing history (1,133 filings)

Recent press releases

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance2026-05-06
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance | TG Therapeutics, Inc.
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance2026-02-26
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance | TG Therapeutics, Inc.
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance2025-11-03
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance | TG Therapeutics, Inc.
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance2025-08-04
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance | TG Therapeutics, Inc.
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance2025-05-05

Similar companies

The largest companies sharing TG THERAPEUTICS, INC.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T TGTX vs LLY

JNJJohnson & Johnson$573.98 B TGTX vs JNJ

ABBVAbbVie Inc.$399.47 B TGTX vs ABBV

MRKMerck & Co., Inc.$293.16 B TGTX vs MRK

AZNAstraZeneca PLC$286.27 B TGTX vs AZN

Frequently asked questions

What is TG THERAPEUTICS, INC.'s market cap?

TG THERAPEUTICS, INC. (TGTX) has a market capitalization of $7.14 B as of 2026-06-10, ranking #1140 among US-listed companies.

How much revenue does TG THERAPEUTICS, INC. make?

TG THERAPEUTICS, INC. reported revenue of $616.29M for fiscal year 2025, an increase of 87.3% year over year.

Is TG THERAPEUTICS, INC. profitable?

Yes. TG THERAPEUTICS, INC. reported net income of $447.20M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.